Synthesis and Utility of New Capgroup Largazole Analogs
US-2018057510-A1 · Mar 1, 2018 · US
Method for preparing largazole analogs and uses thereof
US10676504B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10676504-B2 |
| Application number | US-201615555755-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 3, 2016 |
| Priority date | Mar 6, 2015 |
| Publication date | Jun 9, 2020 |
| Grant date | Jun 9, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of Formula (A) or a pharmaceutically acceptable salt, solvate, clathrate, prodrug, or stereoisomer thereof. 2. A method for treating histone deacetylase (HDAC) responsive cancer in a subject, comprising inhibiting HDAC by administering to the subject a therapeutically effective amount of the compound of claim 1 . 3. The method of claim 2 , further comprising administering to said subject an additional form of therapy for cancer. 4. A method for treating a histone deacetylase (HDAC) responsive blood disorder in a subject, comprising inhibiting HDAC by administering to the subject a therapeutically effective amount of the compound of claim 1 . 5. The method of claim 4 , wherein the blood disorder is at least one of a hemoglobinopathy or a thalassemia. 6. The method of claim 4 , further comprising administering to said subject an additional form of therapy for said blood disorder. 7. The method of claim 2 , wherein the subject is human. 8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and at least one pharmaceutically acceptable excipient wherein the pharmaceutical composition is useful for treating cancer in a subject. 9. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and at least one pharmaceutically acceptable excipient wherein the pharmaceutical composition is useful for treating a blood disorder in a subject. 10. The pharmaceutical composition of claim 9 , wherein the blood disorder is at least one of a hemoglobinopathy or a thalassemia. 11. The pharmaceutical composition of claim 8 , wherein the subject is human. 12. The compound of claim 1 , further comprising a radiolabel.
Assignees
Inventors
Classifications
Bridged systems · CPC title
- A61K31/429Primary
condensed with heterocyclic ring systems · CPC title
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title
Peptides; Proteins · CPC title
Isotopically modified compounds, e.g. labelled · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10676504B2 cover?
- Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
- Who is the assignee on this patent?
- Univ Colorado State Res Found, Dana Farber Cancer Inst Inc, Univ Notre Dame Du Lac
- What technology area does this patent fall under?
- Primary CPC classification A61K31/429. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).